Atherosclerotic Cardiovascular Diseases

Fan J, Watanabe T. Atherosclerosis: Known and unknown. Pathology International. 2022;72:151-160. doi: 10.1111/pin.13202.

Herrington W, Lacey B, Sherliker P, et al. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circulation Research. 2016;118:535-546. doi: 10.1161/circresaha.115.307611.

Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of Atherosclerosis. International Journal of Molecular Sciences. 2022;23:3346. doi: 10.3390/ijms23063346.

Douglas G, Channon KM. The pathogenesis of atherosclerosis. Medicine. 2014;42:480-484. doi: 10.1016/j.mpmed.2014.06.01.

Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. International Journal of Molecular Sciences. 2023;24:7910. doi: 10.3390/ijms24097910.

Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1. Circulation Research. 2016;118:145-156. doi: 10.1161/circresaha.115.306656.

Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduction and Targeted Therapy. 2022;7. doi: 10.1038/s41392-022-00955-7.

Gradinaru D, Borsa C, Ionescu C, et al. Oxidized LDL and NO synthesis—Biomarkers of endothelial dysfunction and ageing. Mechanisms of Ageing and Development. 2015;151:101-113. doi: 10.1016/j.mad.2015.03.003.

Koelwyn GJ, Corr EM, Erbay E, et al. Regulation of macrophage immunometabolism in atherosclerosis. Nature Immunology. 2018;19:526-537. doi: 10.1038/s41590-018-0113-3.

Spinas E, Kritas SK, Saggini A, et al. Role of Mast Cells in Atherosclerosis: A Classical Inflammatory Disease. International Journal of Immunopathology and Pharmacology. 2014;27:517-521. doi: 10.1177/039463201402700407.

Zhu Y, Xian X, Wang Z, et al. Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules. 2018;8:80. doi: 10.3390/biom8030080.

Adukauskienė D, Čiginskienė A, Adukauskaitė A, et al. Clinical relevance of high sensitivity C-reactive protein in cardiology. Medicina. 2016;52:1-10. doi: 10.1016/j.medici.2015.12.001.

Han E, Fritzer-Szekeres M, Szekeres T, et al. Comparison of High-Sensitivity C-Reactive Protein vs C-reactive Protein for Cardiovascular Risk Prediction in Chronic Cardiac Disease. The Journal of Applied Laboratory Medicine. 2022;7. doi: 10.1093/jalm/jfac069.

Held C, White HD, Stewart RAH, et al. Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Journal of the American Heart Association. 2017;6. doi: 10.1161/jaha.116.005077.

Didion S. Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature. International Journal of Molecular Sciences. 2017;18:2563. doi: 10.3390/ijms18122563.

Price DJ, Loscalzo J. Cellular adhesion molecules and atherogenesis. Physiology in Medicine. 1999;107:85-97. doi: 10.1016/s0002-9343(99)00153-9.

Weil BR, Neelamegham S. Selectins and Immune Cells in Acute Myocardial Infarction and Post-infarction Ventricular Remodeling: Pathophysiology and Novel Treatments. Frontiers in Immunology. 2019;10. doi: 10.3389/fimmu.2019.00300.

McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovascular Research. 2015;107:331-339. doi: 10.1093/cvr/cvv154.

Kong D-H, Kim YK, Kim MR, et al. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. International Journal of Molecular Sciences. 2018; 19:1057. doi: 10.3390/ijms19041057.

Singh V, Kaur R, Kumari P, et al. ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2023;548:117487. doi: 10.1016/j.cca.2023.117487.

de Almeida LGN, Thode H, Eslambolchi Y, et al. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacological Reviews. 2022;74:712-768. doi: 10.1124/pharmrev.121.000349.

Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Review of Cardiovascular Therapy. 2007;5:265-282. doi: 10.1586/14779072.5.2.265.

Rašić S, Rebić D, Hasić S, et al. Influence of Malondialdehyde and Matrix Metalloproteinase-9 on Progression of Carotid Atherosclerosis in Chronic Renal Disease with Cardiometabolic Syndrome. Mediators of Inflammation. 2015;2015:1-8. doi: 10.1155/2015/614357.

Luttun A, Lutgens E, Manderveld A, et al. Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth. Circulation. 2004;109:1408-1414. doi: 10.1161/01.cir.0000121728.14930.de.

Konstantino Y, Nguyen TT, Wolk R, et al. Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease. Biomarkers. 2009;14:118-129. doi: 10.1080/13547500902765140.

Zoltán Szekanecz, Kerekes G, Shoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases. European Journal of Internal Medicine. 2023;115:46-47. doi: 10.1016/j.ejim.2023.07.032.

Cinoku II, Mavragani CP, Moutsopoulos HΜ. Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. European Journal of Clinical Investigation. 2020;50. doi: 10.1111/eci.13195.

Sanjadi M, Rezvanie Sichanie Z, Totonchi H, et al. Atherosclerosis and autoimmunity: a growing relationship. International Journal of Rheumatic Diseases. 2018;21:908-921. doi: 10.1111/1756-185x.13309.

Popescu D, Rezus E, Badescu MC, et al. Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy. Life. 2023;13:319. doi: doi.org/10.3390/life13020319.

Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Annals of the Rheumatic Diseases. 2012;71:1524-1529. doi: 10.1136/annrheumdis-2011-200726.

Dzaye O, Dudum R, Reiter-Brennan C, et al. Coronary artery calcium scoring for individualized cardiovascular risk estimation in important patient subpopulations after the 2019 AHA/ACC primary prevention guidelines. Progress in Cardiovascular Diseases. 2019;62:423-430. doi: 10.1016/j.pcad.2019.10.007.

Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases. 2016;76:17-28. doi: 10.1136/annrheumdis-2016-209775.

Behl T, Kaur I, Sehgal A, et al. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. International Journal of Molecular Sciences. 2020;21:9505. doi: 10.3390/ijms21249505.

Hashizume M, Mihara M. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine. 2012;58:424-430. doi: 10.1016/j.cyto.2012.02.010.

Arora A, Ingle V, Joshi R, et al. Exploring the Subclinical Atherosclerotic Load in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Cureus. 2022;14: e32644. doi: 10.7759/cureus.32644.

Venetsanopoulou AI, Pelechas E, Voulgari PV, et al. The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatology International. 2020;40:1181-1191. doi: 10.1007/s00296-020-04616-2.

Robertson J, Peters MJ, McInnes IB, et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology. 2013;9:513-523. doi: 10.1038/nrrheum.2013.91.

Moeinafshar A, Razi S, Rezaei N. Interleukin 17, the double-edged sword in atherosclerosis. Immunobiology. 2022;227:152220. doi: 10.1016/j.imbio.2022.152220.

Yiu KH, Wang S, Mok MY, et al. Role of Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis with Coronary Calcification. The Journal of Rheumatology. 2010;37:529-535. doi: 10.3899/jrheum.090782.

van Vollenhoven R. Treat-to-target in rheumatoid arthritis — are we there yet? Nature Reviews Rheumatology. 2019;15:180-186. doi: 10.1038/s41584-019-0170-5.

Avagimyan A, Fogacci F, Pogosova N, et al. Methotrexate & rheumatoid arthritis associated atherosclerosis: A narrative review of multidisciplinary approach for risk modification by the international board of experts. Current Problems in Cardiology. 2024;49:102230. doi: 10.1016/j.cpcardiol.2023.102230.

Gordeev AV, Galushko EA, Savushkina NM, et al. Assessing the multimorbid profile (CIRS) in rheumatoid arthritis. First results. Modern Rheumatology Journal. 2019;13:10-16. doi: 10.14412/1996-7012-2019-3-10-16.

Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. The American Journal of Cardiology. 2011;108:1362-1370. doi: 10.1016/j.amjcard.2011.06.054.

Accapezzato D, Caccavale R, Maria Pia Paroli, et al. Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2023;24:6578-6578. doi: 10.3390/ijms24076578.

Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Review of Clinical Immunology. 2018;14:1043-1053. doi: 10.1080/1744666x.2018.1538789.

Yang J, Xu D, Shen Z, et al. [Clinical and coronary features of systemic lupus erythematosus patients with coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi. 2012;40:382-385. doi: 10.3760/cma.j.issn.0253-3758.2012.05.006.

Dominika Blachut, Brygida Przywara-Chowaniec, Tomasik A, et al. Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease. Biomedicines. 2023;11:2814-2814. doi: doi.org/10.3390/biomedicines11102814.

Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunologic Research. 2017;65:543-550. doi: 10.1007/s12026-016-8892-9.

Gonzàlez M, Ribalta J, Vives G, et al. Nuclear Magnetic Resonance Lipoprotein Subclasses and the APOE Genotype Influence Carotid Atherosclerosis in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology. 2010;37:2259-2267. doi:.3899/jrheum.091175.

Ronda N, Favari E, Maria Orietta Borghi, et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2013;73:609-615. doi: 10.1136/annrheumdis-2012-202914.

Mak A, Kok J. Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. Nature Reviews Rheumatology. 2022;18:286-300. doi: 10.1038/s41584-022-00770-y.

Infante B, Mercuri S, Dello Strologo A, et al. Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies. International Journal of Molecular Sciences. 2022;23:15998. doi: 10.3390/ijms232415998.

Liu Y, Yu X, Zhang W, Zhang X, Wang M, Ji F. Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus. Journal of Autoimmunity. 2022;132:102863-102863. doi:.1016/j.jaut.2022.102863.

Young Hee Rho, Solus JF, Raggi P, et al. Macrophage activation and coronary atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care and Research. 2011;63:535-541. doi: 10.1002/acr.20365.

Patiño-Trives AM, Pérez-Sánchez C, Pérez-Sánchez L, et al. Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(9):2417-2430. doi: 10.1161/atvbaha.121.315928.

Kobayashi K, Kishi M, Tatsuya Atsumi, et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. Journal of Lipid Research. 2003;44:716-726. doi: 10.1194/jlr.m200329-jlr200.

Talha I, Elkhoudri N, Hilali A. Major Limitations of Cardiovascular Risk Scores. Cardiovascular Therapeutics. 2024;2024:4133365. doi: 10.1155/2024/4133365.

Appleton BD, Major AS. The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. Current Opinion in Rheumatology. 2020;33:211-218. doi: 10.1097/bor.0000000000000773.

Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation. Lupus Science & Medicine. 2019;6:e000346. doi: 10.1136/lupus-2019-000346.

Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2022;81:768-779. doi: 10.1136/annrheumdis-2021-221733.

Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet (London, England). 2022;401. doi: 10.1016/S0140-6736(22)01692-0.

Gerasimova EV, Shayakhmetova RU, Gerasimova DA, Popkova TV, Ananyeva LP. Systemic Sclerosis and Atherosclerosis: Potential Cellular Biomarkers and Mechanisms. Frontiers in bioscience. 2023;15:16-16. doi: 10.31083/j.fbs1504016.

Hesselvig J, Kofoed K, Wu J, Dreyer L, Gislason G, Ahlehoff O. Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study. Acta Dermato Venereologica. 2018;98:361-365. doi: 10.2340/00015555-2842.

Ali H, Ng KR, Low AHL. A qualitative systematic review of the prevalence of coronary artery disease in systemic sclerosis. International Journal of Rheumatic Diseases. 2015;18:276-286. doi:https://doi.org/10.1111/1756-185x.12566

Rotondo C, Sciacca S, Rella V, et al. Subclinical coronary atherosclerosis, detected by computer tomography with coronary calcium score, and the occurrence of major cardiovascular events at 5 years of follow-up in a cohort of patients with systemic sclerosis. European Journal of Internal Medicine. 2023;115:62-69. doi: 10.1016/j.ejim.2023.06.003.

Sanz Pérez, F. Martínez Valle, A. Guillén-del-Castillo, et al. Subclinical cardiovascular disease and Systemic Sclerosis: A comparison between risk charts, quantification of coronary calcium and carotid ultrasonography. Autoimmunity Reviews. 2018;17:900-905. doi: 10.1016/j.autrev.2018.03.015.

Kurmann RD, Sandhu AS, Crowson CS, et al. Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016). Mayo Clinic Proceedings. 2020;95(7):1369-1378. doi: 10.1016/j.mayocp.2019.12.015.

Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences. 2023;24:4901. doi: 10.3390/ijms24054901.

Yiu KH ., Yeung CK ., Zhao CT ., et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. Journal of Internal Medicine. 2013;273:273-282. doi: doi.org/10.1111/joim.12002.

Boehncke WH, Boehncke S, Tobin AM, et al. The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Experimental Dermatology. 2011;20:303-307. doi: 10.1111/j.1600-0625.2011.01261.x.

Shahidi-Dadras M, Haghighatkhah HR, Abdollahimajd F, Younespour S, Partovi Kia M, Zargari O. Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis. International Journal of Dermatology. 2016;55:52-59. doi: 10.1111/ijd.12842.

Saleh HMA, Attia EAS, Onsy AM, et al. Platelet activation: a link between psoriasisper seand subclinical atherosclerosis - a case-control study. British Journal of Dermatology. 2013;169:68-75. doi: 10.1111/bjd.12285.

Tsiogka A, Gregoriou S, Stratigos A, et al. The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review. Biomedicines. 2023;11:318. doi: 10.3390/biomedicines11020318.

Valaiyaduppu Subas S, Mishra V, Busa V, et al. Cardiovascular Involvement in Psoriasis, Diagnosing Subclinical Atherosclerosis, Effects of Biological and Non-Biological Therapy: A Literature Review. Cureus. 2020;12. doi: 10.7759/cureus.11173.

Eder L, Wu Y, Chandran V, et al. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Annals of the Rheumatic Diseases. 2016;75(9):1680-1686. doi: 10.1136/annrheumdis-2015-207980.

Peluso R, Caso F, Tasso M, et al. Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis. Open Access Rheumatology : Research and Reviews. 2019;Volume 11:143-156. doi: 10.2147/oarrr.s206931.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Asymptomatic Hyperuricemia and Serum Uric Acid Concentration Correlate with Subclinical Atherosclerosis in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease. Seminars in Arthritis and Rheumatism. 2009;39:157-162. doi: 10.1016/j.semarthrit.2008.06.001.

Tao LC, Xu J, Wang T, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovascular Diabetology. 2022;21. doi: 10.1186/s12933-022-01511-x.

Xie W, Bian W, Song Z, Deng X, Qu J, Zhang Z. Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology. 2023;62:3584-3591. doi: 10.1093/rheumatology/kead100.

Serhad Bilim, Afitap Içağasioğlu, Ayla Akbal, et al. Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study. Archives of Rheumatology. 2021;36:210-218. doi: 10.46497/archrheumatol.2021.8083.

Natalia Guajardo-Jauregui, Iris Colunga-Pedraza, Jose Azpiri-Lopez, et al. Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients. ACR Meeting Abstracts. 2021. https://acrabstracts.org/abstract/cardiovascular-risk-reclassification-according-to-six-traditional-cardiovascular-risk-algorithms-and-a-carotid-ultrasound-in-psoriatic-arthritis-patients/

Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clinical Rheumatology. 2021;40. doi: 10.1007/s10067-021-05679-7.

Bhattad PB, Kulkarni M, Patel PD, et al. Cardiovascular Morbidity in Ankylosing Spondylitis: A Focus on Inflammatory Cardiac Disease. Cureus. 2022;14. doi: 10.7759/cureus.25633.

Essers I, Stolwijk C, Boonen A, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Annals of the Rheumatic Diseases. 2016;75:203-209. doi: 10.1136/annrheumdis-2014-206147.

Gerasimova EV, Popkova TV, Gerasimova DA, et al. Macrophage Dysfunction in Autoimmune Rheumatic Diseases and Atherosclerosis. International Journal of Molecular Sciences. 2022;23:4513. doi: 10.3390/ijms23094513.

Ahmet Lütfü Sertdemi̇r, Ahmet Taha Sahın, Duran M, et al. Association between syndecan-4 and subclinical atherosclerosis in ankylosing spondylitis. Medicine. 2024;103:e37019-e37019. doi: 10.1097/md.0000000000037019.

Valdivia A, Areli Cárdenas, Brenet M, et al. Syndecan-4/PAR-3 signaling regulates focal adhesion dynamics in mesenchymal cells. Cell Communication and Signaling. 2020;18. doi: 10.1186/s12964-020-00629-3.

Herum KM, Lunde IG, Biljana Skrbic, et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Cardiovascular research. 2015;106(2):217-226. doi: 10.1093/cvr/cvv002.

Hu X, Chen J, Tang W, et al. Effects of exercise programmes on pain, disease activity and function in ankylosing spondylitis: A meta‐analysis of randomized controlled trials. European Journal of Clinical Investigation. 2020;50. doi: 10.1111/eci.13352.

Zimmer S, Goody PR, Oelze M, et al. Inhibition of Rac1 GTPase Decreases Vascular Oxidative Stress, Improves Endothelial Function, and Attenuates Atherosclerosis Development in Mice. Frontiers in Cardiovascular Medicine. 2021;8. doi: 10.3389/fcvm.2021.680775.

Kenan Demır, Ahmet Avcı, Serpil Ergülü Eşmen, et al. Assessment of arterial stiffness and epicardial adipose tissue thickness in predicting the subclinical atherosclerosis in patients with ankylosing spondylitis. Clinical and Experimental Hypertension. 2020;43:169-174. doi: 10.1080/10641963.2020.1833025.

Rueda-Gotor J, Llorca J, Corrales A, et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clinical and Experimental Rheumatology. 2016;34:885-892.